| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/07/2022 | 165.15% | HC Wainwright & Co. | $12 → $7 | Maintains | Buy |
| 10/31/2022 | 127.27% | Piper Sandler | → $6 | Initiates Coverage On | → Overweight |
| 08/22/2022 | -24.24% | Goldman Sachs | → $2 | Downgrades | Neutral → Sell |
| 05/09/2022 | 354.55% | HC Wainwright & Co. | $15 → $12 | Maintains | Buy |
| 03/14/2022 | 468.18% | HC Wainwright & Co. | $24 → $15 | Maintains | Buy |
| 01/20/2021 | 203.03% | Baird | → $8 | Downgrades | Outperform → Underperform |
| 01/20/2021 | 809.09% | HC Wainwright & Co. | $16 → $24 | Maintains | Buy |
| 07/14/2020 | 543.94% | BTIG | $31 → $17 | Maintains | Buy |
| 07/26/2019 | 543.94% | Baird | → $17 | Initiates Coverage On | → Outperform |
| 03/15/2019 | 657.58% | Raymond James | → $20 | Initiates Coverage On | → Outperform |
| 03/07/2019 | 543.94% | HC Wainwright & Co. | → $17 | Initiates Coverage On | → Buy |
| 10/23/2018 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 10/23/2018 | 581.82% | Goldman Sachs | → $18 | Initiates Coverage On | → Neutral |
| 10/23/2018 | 884.85% | BTIG | → $26 | Initiates Coverage On | → Buy |
| 10/23/2018 | 846.97% | Barclays | → $25 | Initiates Coverage On | → Overweight |
Gritstone Bio Questions & Answers
The latest price target for Gritstone Bio (NASDAQ: GRTS) was reported by HC Wainwright & Co. on November 7, 2022. The analyst firm set a price target for $7.00 expecting GRTS to rise to within 12 months (a possible 165.15% upside). 5 analyst firms have reported ratings in the last year.
The latest analyst rating for Gritstone Bio (NASDAQ: GRTS) was provided by HC Wainwright & Co., and Gritstone Bio maintained their buy rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gritstone Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gritstone Bio was filed on November 7, 2022 so you should expect the next rating to be made available sometime around November 7, 2023.
While ratings are subjective and will change, the latest Gritstone Bio (GRTS) rating was a maintained with a price target of $12.00 to $7.00. The current price Gritstone Bio (GRTS) is trading at is $2.64, which is out of the analyst's predicted range.